Healthcare Services

Humira Biosimilar Market Outlook 2026–2030 Exploring New Business Opportunities

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Humira Biosimilar Market Over The 2026–2030 Period?

The humira biosimilar market size has experienced considerable expansion in recent years. It is expected to grow from $3.67 billion in 2025 to $4.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.3%. This historical growth can be attributed to factors such as the patent expiry of humira, the high expenses associated with branded biologic treatments, an increasing occurrence of autoimmune diseases, supportive regulatory frameworks for biosimilar approvals, and pressure from payers to reduce spending on biologic drugs.

The Humira biosimilar market size is anticipated to experience rapid expansion over the coming years, with its value projected to reach $6.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This growth during the forecast period is primarily driven by the broader integration of biosimilars into clinical practice, the enhancement of reimbursement support for these products, a rise in physician confidence regarding biosimilar efficacy, an increase in interchangeable biosimilar approvals, and expanding patient access initiatives for more affordable biologics. Prominent trends throughout this period include the widening adoption of adalimumab biosimilars across various autoimmune indications, a stronger focus on cost containment strategies within biologic therapies, increasing acceptance of interchangeable biosimilars among healthcare providers, a growing preference for high-concentration and citrate-free formulations, and intensifying competition among manufacturers of biosimilars.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp

Which Economic Or Industry Drivers Are Impacting The Humira Biosimilar Market?

The humira biosimilar market is anticipated to expand due to the rising occurrence of autoimmune conditions. These diseases manifest when the body’s immune system erroneously attacks its own healthy cells, tissues, or organs. A rise in these conditions is associated with environmental pollution, which can interfere with the immune system and increase the likelihood of autoimmune responses. Humira biosimilars function by inhibiting tumor necrosis factor (TNF), a protein responsible for inflammation in autoimmune disorders. This mechanism aids in lowering the immune response, thereby easing symptoms and safeguarding healthy tissues from damage. As an illustration, data released in August 2024 by Public Health Scotland, a national organization based in Scotland, indicated that the Scottish Multiple Sclerosis Register (SMSR) registered 455 new MS diagnoses in 2023. Consequently, the expanding incidence of autoimmune diseases is fueling the development of the humira biosimilar market.

How Is The Humira Biosimilar Market Segmented Across Key Categories?

The humira biosimilar market covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars, High-Concentration Adalimumab Biosimilars, Citrate-Free Adalimumab Biosimilars

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Citrate-Containing, Standard-Concentration Formulations, Citrate-Free, Standard-Concentration Formulations

2) By High-Concentration Adalimumab Biosimilars: Citrate-Containing High-Concentration Formulations, Citrate-Free High-Concentration Formulations

3) By Citrate-Free Adalimumab Biosimilars: Standard-Concentration Citrate-Free Formulations, High-Concentration Citrate-Free Formulations

What Trends Are Affecting The Expansion Of The Humira Biosimilar Market?

Major companies in the humira biosimilar market are concentrating on developing advanced products, such as tumor necrosis factor (TNF) blockers, to provide more economical choices for managing autoimmune diseases. Tumor necrosis factor (TNF) blockers are biologic drugs that inhibit the activity of TNF, a critical protein that stimulates inflammation. For instance, in July 2023, Organon & Co., a US-based pharmaceutical company, partnered with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, to introduce HADLIMA, a biosimilar to Humira. HADLIMA is available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) versions, mirroring the options of the original Humira, and aims to enhance patient access and affordability. The product is offered at a considerable discount, approximately 85% lower than Humira’s list price, and includes support programs for patients. This launch follows a global settlement allowing U.S. supply and represents a significant achievement in expanding treatment alternatives for chronic autoimmune diseases in the U.S.

Who Are The Dominant Players Shaping The Humira Biosimilar Market Landscape?

Major companies operating in the humira biosimilar market are Amgen Inc., Pfizer Inc., Samsung Biologics, Biocon Limited, Celltrion Inc., Boehringer Ingelheim GmbH, Sandoz Group AG, Fresenius Kabi AG, Alvotech, Coherus BioSciences Inc., Zydus Lifesciences Ltd., Hetero Drugs Ltd., LG Chem Ltd., Torrent Pharmaceuticals Ltd., Fujifilm Holdings Corporation, Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon & Co., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

Read the full humira biosimilar market report here:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

What Are The Top-Performing Regions Within The Humira Biosimilar Market?

North America was the largest region in the humira biosimilar market in 2025. The regions covered in the humira biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Humira Biosimilar Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp

Browse Through More Reports Similar to the Global Humira Biosimilar Market 2026, By The Business Research Company

Humic Based Biostimulants Market Global Market Report

https://www.thebusinessresearchcompany.com/report/humic-based-biostimulants-market-global-market-report

Biosimulation Global Market Report

https://www.thebusinessresearchcompany.com/report/biosimulation-global-market-report

Biosimilar Global Market Report

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795